Collaborative Arrangements and Licensing Agreements (Tables)

6 Months Ended

Jun. 30, 2023

AstraZeneca [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and six months ended June 30, 2023 and 2022, we earned the following revenue from our relationship with AstraZeneca (in thousands, except percentages):

	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Revenue from our relationship with AstraZeneca	$	59,501		$	17,768		$	83,926		$	37,611
Percentage of total revenue		32	%		13	%		26	%		14	%

Biogen [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and six months ended June 30, 2023 and 2022, we earned the following revenue from our relationship with Biogen (in thousands, except percentages):

	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Revenue from our relationship with Biogen	$	97,402		$	76,887		$	167,903		$	170,754
Percentage of total revenue		52	%		58	%		53	%		62	%

GSK [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and six months ended June 30, 2023 and 2022, we earned the following revenue from our relationship with GSK (in thousands, except percentages):

	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Revenue from our relationship with GSK	$	—		$	—		$	15,000		$	—
Percentage of total revenue		0	%		0	%		5	%		0	%